http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jiajia Bi (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Jiajia Bi,Xianlu Zeng,Ruifei Wang,Yue Zhang,Xiaoqing Han,Khamal Kwesi Ampah,Wenguang Liu 한국분자세포생물학회 2013 Molecules and cells Vol.36 No.6
Lipid rafts are related to cell surface receptor function. Integrin is a major surface receptor protein in cell adhesion and migration on the extracellular matrix (ECM). Here, we showed that lipid rafts played a critical role in human melanoma A375 cell spreading and migration on fibronectin; an important component of the ECM that interacts with 1 integrin. We found that the disruption of lipid rafts did not markedly inhibit the expression and activation of 1 integrin. By coimmunoprecipitation and mass spectrometry, we investigated the influence of lipid rafts on the 1 integrin complex and identified nucleolin as a potential lipid-raft-dependent 1-integrin-interacting protein. Upon confirmation of the interaction between 1 integrin and nucleolin, further studies revealed that nucleolin colocalized with 1 integrin in lipid rafts and raft disruption interrupted their association. In addition, knockdown of nucle-olin markedly attenuated A375 cell spreading and migration on fibronectin. Taken together, we demonstrated that nucleolin is a critical lipid-raft-dependent 1-integrin-inte-racting protein in A375 cell spreading and migration on fibronectin.
-
An Adaptive Cellular Genetic Algorithm Based on Selection Strategy for Test Sheet Generation
Ankun Huang,Dongmei Li,Jiajia Hou,Tao Bi 보안공학연구지원센터 2015 International Journal of Hybrid Information Techno Vol.8 No.9
Intelligent test sheet generation is a multi-objective constrained optimization problem. Genetic algorithm based on groups search strategy can provide a better solution for multi-objective optimization. Traditional genetic algorithm in test sheet generation process has many drawbacks, such as poor convergence, low fitness and high exposure times. To solve these problems, this paper proposes an adaptive cellular genetic algorithm based on selection strategy. Selection strategy can adaptively determine candidate test items set and the conceptual granularities according to the desired concept scope. Then, a new cellular population is formed by candidate test items. After evolution by the rule, genetic algorithms are executed. The experimental results show that the proposed algorithm gets rid of tests that do not meet the requirements which can reduce knowledge related errors, lower the exposure of tests, and increase the possibility of escape from local optima. In general, the algorithm proposed in this paper effectively improves the convergence speed as well as generates test papers more in line with people's demands.
-
Kuikui Jiang,Ruoxi Hong,Wen Xia,Qianyi Lu,Liang Li,Jianhao Huang,Yanxia Shi,Zhongyu Yuan,Qiufan Zheng,Xin An,Cong Xue,Jiajia Huang,Xiwen Bi,Meiting Chen,Jingmin Zhang,Fei Xu,Shusen Wang 대한암학회 2024 Cancer Research and Treatment Vol.56 No.2
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
